Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Covax-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Prestige BioPharma Pte Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through MOU, Prestige and Vaxine will be building a partnership, initially focused on manufacturing and commercialization of Vaxine’s Covid-19 vaccine, Covax-19® and then as Covid-19 enters an endemic phase development of a next generation Covid19/inf...
Brand Name : Spikogen
Molecule Type : Vaccine
Upfront Cash : Undisclosed
March 30, 2022
Lead Product(s) : Covax-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Prestige BioPharma Pte Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : SARS-CoV-2 Recombinant Spike Protein,Advax-SM
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : CinnaGen Co
Deal Size : Not Applicable
Deal Type : Not Applicable
CinnaGen Protein Subunit Covid-19 Vaccine Phase III Results Likely Within Two Months
Details : SpikoGen features the SARS-CoV-2 spike protein and Vaxine’s own Advax-SM adjuvant. The placebo-controlled SpikoGen trial has coprimary endpoints investigating the occurrence of symptomatic Covid-19 and severe Covid-19, with both endpoints.
Brand Name : SpikoGen
Molecule Type : Vaccine
Upfront Cash : Not Applicable
September 16, 2021
Lead Product(s) : SARS-CoV-2 Recombinant Spike Protein,Advax-SM
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : CinnaGen Co
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : COVAX-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Medytox
Deal Size : Undisclosed
Deal Type : Collaboration
Vaxine and Medytox partner on Covid-19 vaccine development
Details : The collaboration aims at developing a Covid-19 vaccine called, COVAX-19®, which is currently undergoing late stage animal testing and is based on Vaxine’s proprietary Advax™ adjuvant technology combined with a recombinant SARS-CoV-2 spike protein.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
May 25, 2020
Lead Product(s) : COVAX-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Medytox
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?